Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

The California-based nonprofit founded by the former 23andMe CEO is set to close the $305 million deal in coming weeks.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

TTAM replaces biotech company Regeneron as 23andMe's buyer. Last month, Regeneron won the bidding during the bankruptcy ...

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

June 13 (Reuters) - Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals’ REGN.O offer for the DNA-testing company ...

Former 23andMe CEO Anne Wojcicki is set to regain control of the genetic testing firm she led to bankruptcy after outbidding a pharmaceutical company at an auction. The sale came on Monday after a ...

Former CEO Anne Wojcicki has prevailed in the bankruptcy auction of 23andMe, its consumer and biopharma research businesses, ...

Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a ...

The genetic testing company 23andMe is poised to be sold to a nonprofit run by the company's former chief executive Anne ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron ...

Anne Wojcicki is set to regain control of 23andMe after a nonprofit she controls topped Regeneron Pharmaceuticals' bid for ...